ORGO vs. AMRN, ANRO, FBLG, TERN, RVNC, ACIU, KRRO, VRCA, STTK, and NGNE
Should you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Amarin (AMRN), Alto Neuroscience (ANRO), FibroBiologics (FBLG), Terns Pharmaceuticals (TERN), Revance Therapeutics (RVNC), AC Immune (ACIU), Korro Bio (KRRO), Verrica Pharmaceuticals (VRCA), Shattuck Labs (STTK), and Neurogene (NGNE). These companies are all part of the "pharmaceutical preparations" industry.
Amarin (NASDAQ:AMRN) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.
Organogenesis has a net margin of 1.34% compared to Organogenesis' net margin of -18.96%. Amarin's return on equity of 2.11% beat Organogenesis' return on equity.
Amarin received 746 more outperform votes than Organogenesis when rated by MarketBeat users. Likewise, 74.45% of users gave Amarin an outperform vote while only 66.21% of users gave Organogenesis an outperform vote.
Amarin presently has a consensus price target of $1.08, suggesting a potential upside of 24.52%. Organogenesis has a consensus price target of $4.83, suggesting a potential upside of 76.40%. Given Amarin's stronger consensus rating and higher possible upside, analysts plainly believe Organogenesis is more favorable than Amarin.
Organogenesis has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.
22.3% of Amarin shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 2.0% of Amarin shares are held by company insiders. Comparatively, 34.0% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Amarin has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.
In the previous week, Organogenesis' average media sentiment score of 0.36 beat Amarin's score of 0.00 indicating that Amarin is being referred to more favorably in the media.
Summary
Organogenesis beats Amarin on 12 of the 17 factors compared between the two stocks.
Get Organogenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organogenesis Competitors List
Related Companies and Tools
